Navigation Links
Maximizing Pharmaceutical Licensing Opportunities
Date:7/11/2011

NEW YORK, July 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Maximizing Pharmaceutical Licensing Opportunities

http://www.reportlinker.com/p0570472/Maximizing-Pharmaceutical-Licensing-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Introduction

The report reviews the key trends in pharmaceutical licensing, examining deal volumes, values and structure. Therapeutic focus is also covered along with detailed profiles of the strategies of 10 leading pharmaceutical companies. The report also sets out future directions for licensing and alliance activity.

Features and benefits

* Understand why licensing deals have become an integral part of Big Pharma strategies, along with the future impact of these strategies.

* Identify the factors that are crucial to success in the licensing sphere, and the potential pitfalls that must be avoided.

* Learn how leading players manage the licensing process, and pinpoint changes in their approach to licensing strategy.

* Track recent changes in deal-making volumes, in-licensing/out-licensing ratios and the type of assets being targeted in major transactions.

* Quantify financial commitments by licensees to external assets, and understand why the financial structure of licensing deals has begun to change.

Highlights

For an increasingly risk-averse industry, licensing deals represent a more affordable, less risky alternative to M&A transactions. They are being used to strengthen pipelines, manage major brand life-cycles, expand or restructure portfolios, access new technologies, and enter new geographical markets.

Cancer has emerged as the therapeutic area in which most deals are being struck. Other key therapy area targets include infectious disease, CNS disorders, metabolic/endocrine disease and auto-immune/inflammatory conditions. Rights to assets in these five therapy areas were traded in around two-thirds of all deals.

Declared financial commitments to assets licensed by the world's ten biggest pharmaceutical companies totaled more than US$78bn in the five-year period to 2010. GSK was the biggest contributor to that figure, signing deals involving up-front fees and potential milestone payments that could exceed US$19bn.

Your key questions answered

* Why do a growing number of Big Pharma CEOs favor licensing and alliance deals over M&A transactions?

* How do leading multinationals structure their licensing activities, and how are approaches changing?

* What factors lie behind the recent upturn in deal-making volumes, and will the increase be sustained?

* Which therapy areas are the subject of most licensing deals?

* Which companies top the Big Pharma licensing league in terms of deal volumes and financial commitments?

Executive Summary

Pharmaceutical licensing

Pharmaceutical licensing trends

Big Pharma licensing profiles

Future trends in pharma licensing

About the author

Disclaimer

Pharmaceutical licensing

Summary

Introduction

Mega-trends behind the pharma licensing boom

An industry in flux

Looking out, not in

Licensing

Licensing versus M&A

Goals and targets

Procedures and approaches

Pharmaceutical licensing trends

Summary

Introduction

Deal volumes

The deal-making community

Licensing targets

Deal values

Up-front payments

Milestone payments

Big Pharma licensing profiles

Summary

Introduction

Big Pharma deal-making volumes

Financial commitments to in-licensed assets

Leading therapy area targets

Strategic deal making focus

In-licensing strategies

Pfizer

Licensing strategy

Licensing activity

Novartis

Licensing strategy

Licensing activity

Sanofi

Licensing strategy

Licensing activity

Merck & Co.

Licensing strategy

Licensing activity

GlaxoSmithKline

Licensing strategy

Licensing activity

Roche

Licensing strategy

Licensing activity

AstraZeneca

Licensing strategy

Licensing activity

Johnson & Johnson

Licensing strategy

Licensing activity

Eli Lilly

Licensing strategy

Licensing activity

Abbott

Licensing strategy

Licensing activity

Future trends in pharma licensing

Summary

Introduction

Filling Big Pharma pipelines

Accessing novel technologies

Choice of licensing partners

Hedging risks associated with pharmaceutical R&D

Increasing patient focus

Portfolio restructuring

Beyond pharmaceutical licensing

Appendix

Scope

Methodology

To order this report:

Pathology Industry: Maximizing Pharmaceutical Licensing Opportunities

Pathology Business News

More  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioInformatics, LLC New Market Report - Life Science Instruments: Maximizing Market Share
2. Maximizing the Potential of Internal and External Communications Groups
3. Maximizing the Potential of Multi-Drug Portfolios without Undermining a Legacy Brand
4. PAREXEL Expert Serves as Lead Author and Editor of Definitive Resource on Quality by Design (QbD), Aimed at Maximizing Product Quality and Speeding Treatments to Market
5. Maximizing the Potential of Multi-Drug Portfolios Without Cannibalizing from a Legacy Brand
6. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
7. Valeant Pharmaceuticals Agrees to Acquire Dermik
8. HUYA BIOSCIENCE INTERNATIONAL ENGAGES IN PARTNERSHIP WITH LIAONING (BENXI) BIO-PHARMACEUTICAL INDUSTRY BASE
9. Par Pharmaceutical Companies to Report Second Quarter 2011 Results on August 3, 2011
10. JHP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin®
11. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):